GeneDx — Third Quarter 2026 Earnings Summary

GeneDx Holdings Corp. reported third-quarter 2026 revenue of $123.1 million, representing a 5% year-over-year increase driven by a 12% rise in exome and genome test revenue. The company achieved adjusted gross margins of 72% and adjusted net income of $8.6 million, while exome and genome test volumes grew 25% year-over-year to 32,134 tests. GeneDx reiterated its full-year 2026 revenue guidance of $475 million to $490 million and announced strategic expansions including new Medicaid coverage in Arkansas and Utah, alongside partnerships for sponsored testing programs. The company also highlighted clinical advancements in rapid genome sequencing and genomic newborn screening initiatives.